Gynostemma

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: longevity immunity inflammation

Research Overview

Across the reviewed literature, research on Gynostemma—especially Gynostemma pentaphyllum (Jiaogulan)—is dominated by ethnopharmacology, phytochemistry, and preclinical pharmacology. The most intensively studied constituents are dammarane-type saponins (gypenosides), with large-scale compound isolation reported (hundreds of structurally characterized saponins), alongside polysaccharides, flavonoids, and phytosterols. The most frequently investigated therapeutic areas align with traditional uses and modern chronic-disease targets: metabolic disorders (diabetes, obesity, metabolic syndrome, dyslipidemia), cardiovascular-related endpoints (e.g., anti-atherogenic/cardioprotective effects and hypertension-related indications), liver diseases (hepatoprotection and fatty liver), inflammation, and neuroprotection/aging-associated conditions. Mechanistic work commonly centers on anti-inflammatory signaling (e.g., NF-κB/MAPK modulation and COX/LOX-related pathways) and, more recently, interactions between saponins and the gut microbiome as a potential mediator of systemic metabolic and immune effects.

The strongest evidence supported by these studies is that G. pentaphyllum contains bioactive saponins and other phytochemicals that produce reproducible biological effects in in vitro and animal models, particularly anti-inflammatory and metabolic-regulatory activities, with downstream relevance to cardiometabolic and liver outcomes. Reviews also converge on a broad preclinical signal for hepatoprotective, cardioprotective, anti-diabetic/anti-obesity, and anti-inflammatory actions, and they highlight plausible mechanistic pathways (including immune signaling modulation and microbiome-associated effects). Safety evidence is comparatively limited but suggests that G. pentaphyllum extracts were “relatively safe” in available acute and longer-term animal toxicology studies at tested doses; however, this safety characterization is not yet comprehensive and is largely restricted to this single species.

Key gaps are clinical translation and standardization. Multiple reviews explicitly note the need for well-designed human studies to evaluate efficacy, dose–response, and adverse effects of crude extracts, standardized gypenoside fractions, and purified compounds, as well as to quantify herb–drug interaction risks (particularly relevant for cardiovascular and metabolic patients on polypharmacy). Additional needs include: (1) more rigorous toxicology for other Gynostemma species used as substitutes (e.g., G. longipes, G. laxum), (2) improved quality control/chemical standardization across preparations, (3) clearer causal evidence linking microbiome modulation to clinical endpoints in liver and inflammatory diseases, and (4) comparative studies to identify which constituents (saponins vs. polysaccharides/flavonoids) drive specific therapeutic effects. Overall, the field is rich in phytochemical and preclinical data but remains limited by a relative scarcity of confirmatory clinical and safety studies.

1. What conditions has Gynostemma been studied for?

  • Metabolic diseases: type 2 diabetes mellitus (T2DM), metabolic syndrome, obesity, and related complications (e.g., diabetic retinopathy) are repeatedly cited as traditional uses and research targets.

  • Cardiovascular-related conditions/risk factors: hypertension, atherosclerosis/anti-atherogenic effects, and broader “cardioprotective” effects are described in reviews; one review frames medicinal herbs (including Gynostemma) as being studied for cardiovascular disease (CVD) risk-factor modulation.

  • Liver diseases: hepatosteatosis/fatty liver and “liver injury” broadly; one review specifically discusses Gynostemma among traditional medicines/natural products that may improve fatty liver and liver immunity via gut microbiota-related mechanisms.

  • Inflammation and immune regulation: saponins (including from Gynostemma pentaphyllum) are reviewed for anti-inflammatory mechanisms (e.g., NF-κB/MAPK regulation, COX/LOX inhibition) and gut microbiome interactions; an animal study used a multi-herb formula containing Gynostemma to counter opioid-induced immunosuppression.

  • Neurodegenerative/brain-related conditions: neurodegenerative diseases are mentioned in ethnopharmacology; reviews also cite anti-dementia and anti-Parkinson’s-related activities (largely preclinical).

  • Cancer: anti-cancer activity is described in reviews (primarily in vitro/in vivo preclinical evidence).

  • Aging/aging-associated conditions: included in an “anti-aging phytotherapeutics” review, with gypenosides discussed among active components targeting pathways linked to aging and cardiovascular risk.

  • Infectious susceptibility under immunosuppression: in morphine-immunosuppressed mice, a Gynostemma-containing formula reduced susceptibility/severity of MRSA lung inflammation.

2. Does it work in treating those conditions? Summarize the evidence.

  • Overall state of evidence: mostly preclinical and review-based; limited clinical confirmation. The genus review (to Feb 2020) concludes that while extracts, saponin-rich fractions (gypenosides), and isolated compounds show broad activity in vitro and in vivo, “clinical data are required” to evaluate efficacy and undesired effects of crude extracts/standardized fractions/pure compounds.

  • Diabetic retinopathy (DR): supportive animal + cell evidence for a specific compound formulation. A study of gypenoside A nanoparticles (GPA-NP) in DR mice and high-glucose–exposed human retinal microvascular endothelial cells reported that GPA-NP (vs GPA alone) improved bioavailability and more strongly reduced oxidative stress markers and inflammatory cytokines, and protected against endothelial ferroptosis via Nrf2/HO-1/GPX4 pathway activation (by disrupting Nrf2–Keap1 interaction). This supports mechanistic plausibility and efficacy in models, not yet in humans.

  • Metabolic conditions (T2DM/obesity/metabolic syndrome): promising but largely non-clinical in these studies. Multiple reviews state traditional use and report anti-diabetic and anti-obesity effects in animal/cell studies, but the studies reviewed here do not include human trial outcomes or effect sizes.

  • Liver disease/fatty liver: suggestive, mechanism-oriented review evidence. A gut microbiota–liver disease review lists Gynostemma among traditional medicines/natural products reported to improve liver injury/fatty liver and regulate immunity, with effects “closely related to the gut microbiota.” This is a synthesis of multiple studies rather than a single confirmatory clinical trial.

  • Immune effects under opioid exposure: indirect evidence for Gynostemma specifically. In mice, Compound 511 (an 8-herb formula containing 10.95% G. pentaphyllum) improved morphine-induced immunosuppression markers (corrected Th1/Th2 and Th17/Treg imbalance; involved PI3K/AKT/mTOR signaling) and reduced MRSA lung inflammation. Because it is a multi-herb formula, the study does not isolate the contribution of Gynostemma alone.

  • CVD/cardioprotection/anti-atherogenic effects: mainly review-level and preclinical. Reviews describe cardioprotective and anti-atherogenic activities and note herbs can modulate CVD risk factors, but the studies reviewed here do not present controlled human outcomes for Gynostemma.

3. What health benefits does it have?

  • Anti-inflammatory potential: saponin-focused reviews describe anti-inflammatory mechanisms including regulation of NF-κB and MAPK pathways and inhibition of COX/LOX enzymes; Gynostemma is cited as an example of saponin–gut microbiome–immune/metabolic interactions.

  • Metabolic support (preclinical): reviews report anti-diabetic, hypoglycemic, lipid-regulating, and anti-obesity activities for extracts/gypenosides in vitro/in vivo.

  • Cardiometabolic risk reduction (preclinical/review): cardioprotective and anti-atherogenic activities are described, and an anti-aging review links gypenosides to pathways relevant to cardiovascular risk (e.g., SIRT1/AMPK, PI3K/Akt, NF-κB, insulin/IGF-1 signaling).

  • Hepatoprotective effects (preclinical/review): reviews cite hepatoprotective activity and use in hepatosteatosis; another review emphasizes potential gut microbiota–mediated benefits in liver diseases.

  • Neuroprotective signals (preclinical/review): neuroprotective, anti-dementia, and anti-Parkinson’s-related activities are summarized in reviews (primarily from cell/animal studies).

  • Antioxidant/cytoprotective mechanisms: the DR study supports antioxidant/anti-ferroptotic effects via Nrf2 pathway activation; the anti-aging review also discusses antioxidant activity and improved resistance to DNA damage for plant compounds including gypenosides.

4. Does it have any downsides or side effects?

  • Safety evidence is incomplete. A cardiovascular-herb review cautions broadly that herbal preparations’ claimed safety is often not properly tested and highlights potential toxicity and herb–drug interactions as public health concerns.

  • Toxicology data exist mainly for G. pentaphyllum, not the whole genus. The genus review reports toxicological studies were conducted only on G. pentaphyllum, and that extracts were “relatively safe” in acute and long-term toxicity experiments at the tested dosages; it also notes no toxicological studies were reported for other Gynostemma species.

  • Formulation/compound-specific concerns: potential cardiotoxicity and poor bioavailability were noted for gypenoside A. The DR abstract explicitly states gypenoside A has “poor bioavailability and potential cardiotoxicity” limiting clinical application; nanoparticle encapsulation was used to address these issues. This indicates that at least some isolated constituents may have safety liabilities even if crude extracts appear relatively safe in some studies.

  • Herb–drug interaction risk is plausible but not defined here. The studies reviewed here do not specify particular interactions for Gynostemma, but given its reported effects on immune signaling (e.g., PI3K/AKT/mTOR in an animal model) and inflammation pathways (NF-κB/MAPK), interaction potential with immunomodulators/anti-inflammatories is a reasonable concern that requires clinical study.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report pharmacogenomic findings for Gynostemma (e.g., effects modified by specific genetic variants in drug-metabolizing enzymes/transporters or target genes).

  • No direct evidence in these studies linking Gynostemma response or toxicity to human genetic polymorphisms (such as CYP450 variants, transporter variants, or pathway gene variants).

  • Mechanistic pathways are mentioned but not tied to genotype. Reviews and studies reference pathways (e.g., NF-κB, MAPK, PI3K/Akt/mTOR, SIRT1/AMPK, Nrf2/Keap1), which could theoretically vary by genotype, but no genotype-stratified outcomes are provided.

References

  1. Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety.
    Abdullah Shaito, Duong Thi Bich Thuan, Hoa Thi Phu, Thi Hieu Dung Nguyen, Hiba Hasan, Sarah Halabi, Samar Abdelhady, Gheyath K Nasrallah, Ali H Eid, Gianfranco Pintus (2020) - Frontiers in pharmacology
  2. Critical review on anti-inflammation effects of saponins and their molecular mechanisms.
    Tharuka Wijesekara, Jinhai Luo, Baojun Xu (2024) - Phytotherapy research : PTR
  3. Triterpenoids from the genus Gynostemma: Chemistry and pharmacological activities.
    Ngoc-Hieu Nguyen, Thi Kim Quy Ha, Jun-Li Yang, Ha Thanh Tung Pham, Won Keun Oh (2021) - Journal of ethnopharmacology
  4. Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy.
    Li-Ran Zhu, Shan-Shan Li, Wan-Qun Zheng, Wei-Jian Ni, Ming Cai, Hai-Peng Liu (2023) - Frontiers in immunology
  5. Progress in the Medicinal Value, Bioactive Compounds, and Pharmacological Activities ofGynostemma pentaphyllum
    Chao Su, Nan Li, Ruru Ren, Yingli Wang, Xiaojuan Su (2021)
  6. Herbal Medicine for Slowing Aging and Aging-associated Conditions: Efficacy, Mechanisms and Safety.
    Hoa T Phu, Duong T B Thuan, Thi H D Nguyen, Anna M Posadino, Ali H Eid, Gianfranco Pintus (2020) - Current vascular pharmacology
  7. Gypenosides ameliorate high-fat diet-induced nonalcoholic fatty liver disease in mice by regulating lipid metabolism.
    Tingting Zhou, Ligang Cao, Yimei Du, Lin Qin, Yanliu Lu, Qianru Zhang, Yuqi He, Daopeng Tan (2023) - PeerJ
  8. Compound 511 ameliorates MRSA-induced lung injury by attenuating morphine-induced immunosuppression in mice via PI3K/AKT/mTOR pathway.
    Zhonghao Li, Qinmei Sun, Qingyang Liu, Xinru Mu, Hui Wang, Han Zhang, Fenfen Qin, Qisheng Wang, Dengyun Nie, Anlong Liu, Qian Li, Jianjian Ji, Yongwei Jiang, Shengfeng Lu, Qian Wang, Zhigang Lu (2023) - Phytomedicine : international journal of phytotherapy and phytopharmacology
  9. Gypenoside A-loaded mPEG-PLGA nanoparticles ameliorate high-glucose-induced retinal microvasculopathy by inhibiting ferroptosis.
    Qin Chen, Fen-Sheng Qiu, Wei Xie, Wen-Ying Yu, Zhao-An Su, Guang-Ming Qin, You-Kun Kang, Song-Lin Jiang, Chen-Huan Yu (2024) - International journal of pharmaceutics
  10. Gynostemma PentaphyllumExtract Ameliorates High-Fat Diet-Induced Obesity in C57BL/6N Mice by Upregulating SIRT1
    Hyun Sook Lee, Su-Min Lim, Jae In Jung, So Mi Kim, Jae Kyoung Lee (2019)
  11. Neuroprotective effects of gypenosides on LPS-induced anxiety and depression-like behaviors.
    Mei Guo, Wen-Jing Pei, Liming Liu, Kexuan Chen, Yong Cheng, Xiang-Lan Piao (2024) - International immunopharmacology
  12. Protopanaxadiol ameliorates NAFLD by regulating hepatocyte lipid metabolism through AMPK/SIRT1 signaling pathway.
    Yiping Li, Yang Liu, Zhiwei Chen, Kaiyue Tang, Lili Yang, Yuwei Jiang, Jue Wang, Ping Huang, Jianyi Wang, Peiyong Zheng, Haiyan Song (2023) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  13. Gynostemma pentaphyllum Extract Alleviates NASH in Mice: Exploration of Inflammation and Gut Microbiota.
    Feng-Yan Jiang, Si-Ran Yue, Yi-Yun Tan, Nan Tang, Yue-Song Xu, Bao-Jun Zhang, Yue-Jian Mao, Zheng-Sheng Xue, Ai-Ping Lu, Bao-Cheng Liu, Rui-Rui Wang (2024) - Nutrients
  14. Further New Gypenosides from Jiaogulan (Gynostemma pentaphyllum).
    Jun Wang, Jun-Li Yang, Pan-Pan Zhou, Xian-Hua Meng, Yan-Ping Shi (2017) - Journal of agricultural and food chemistry
  15. Hypolipidemic effect and gut microbiota regulation of Gypenoside aglycones in rats fed a high-fat diet.
    Jian Xie, Mingxia Luo, Qiuyi Chen, Qianru Zhang, Lin Qin, Yuhe Wang, Yongxia Zhao, Yuqi He (2024) - Journal of ethnopharmacology
  16. New dammarane-type glycosides from Gynostemma pentaphyllum and their lipid-lowering activity.
    Xin Weng, Yun-Yun Lou, Yun-Shan Wang, Ya-Ping Huang, Jian Zhang, Zhi-Qi Yin, Ke Pan (2021) - Bioorganic chemistry
  17. Dammarane-type saponins from Gynostemma pentaphyllum and their anti-aging activities via up-regulating mitochondria related proteins.
    Hai-Zhen Liang, Peng-Xin Lu, Li-Li Chu, Gang Li, Chuan-Biao Li, Xiao-Juan Chen, Jie Zhang, Juan Song, Tao Zhang, Ying Luo, Ying Hu, Bai-Ping Ma (2023) - Phytochemistry
  18. Ethnobotanical study on herbal tea drinks in Guangxi, China.
    Tingyu Long, Renchuan Hu, Zhuo Cheng, Chuangui Xu, Qimin Hu, Qingling Liu, Ronghui Gu, Yunfeng Huang, Chunlin Long (2023) - Journal of ethnobiology and ethnomedicine
  19. Gypenosides protect retinal pigment epithelium cells from oxidative stress.
    Reem Hasaballah Alhasani, Lincoln Biswas, Ali Mohammad Tohari, Xinzhi Zhou, James Reilly, Jian-Feng He, Xinhua Shu (2018) - Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association


Related

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!